Coya Therapeutics (COYA) announces that the FDA has accepted its Investigational New Drug, or IND, application for COYA 302. This proprietary immunomodulatory biologic combination therapy is being developed for the treatment of patients with amyotrophic lateral sclerosis, or ALS. The approval of the IND by the FDA triggers a $4.2M milestone payment to Coya from DRL.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Positive Outlook for Coya Therapeutics Amid Promising Developments and Financial Stability
- Coya Therapeutics Reports Increased Losses Amid Development Focus
- Coya Therapeutics files $75M mixed securities shelf
- Coya Therapeutics Highlights Q2 2025 Financial Results
- Coya Therapeutics reports Q2 EPS (36c), consensus (43c)